Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06737016
PHASE3

Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.

Sponsor: Mansoura University

View on ClinicalTrials.gov

Summary

To determine whether there is a role for Tamsulosin, A Selective Alpha-1 Adrenergic Blocker, as therapy in children with Posterior Urethral Valve post valve ablation , and whether there are side effects involved.

Official title: Efficacy and Safety of Tamsulosin, a Selective Alpha-1 Adrenergic Blocker, for Children with Posterior Urethral Valve: a Randomized Controlled Trial

Key Details

Gender

MALE

Age Range

Any - 12 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2024-11-01

Completion Date

2026-11

Last Updated

2024-12-20

Healthy Volunteers

No

Interventions

DRUG

Tamsulosin

Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).

DRUG

Oxybutynin

Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.

DRUG

Trimethoprim/sulfamethoxazole (TMP/SMZ)

Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.

Locations (1)

Mansoura Urology and Nephrology Center

Al Mansurah, Dakahlia Governorate, Egypt